<DOC>
	<DOCNO>NCT00581126</DOCNO>
	<brief_summary>To assess efficacy safety BeneFixÂ® prophylaxis `` Short-term '' therapy demand therapy bleed episode subject hemophilia B .</brief_summary>
	<brief_title>Study Evaluating BENEFIX Previously Treated Patients With Hemophilia B</brief_title>
	<detailed_description>Phase IV , open-label , non comparative , multicenter , previously treat patient ( PTP ) clinical trial . Patients severe moderate hemophilia B baseline level plasma factor IX &lt; 5 % activity participate study treatment regimen : `` demand '' therapy acute bleed episode therapy prophylaxis bleed episode ( `` Short-term therapy '' ) * . * Short-Term Therapy : Prophylactic therapy give surgery , include dental procedure , prior event would likely result bleed ( sport , exercise , heavy work ) , well prevent bleeds target joint ) . This short-term therapy intermittent secondary therapy .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Patients moderate severe hemophilia B ( &lt; 5 % circulate factor IX activity ) acute hemorrhage require `` shortterm therapy '' intermittent secondary prophylaxis regimen . 2 . HIV seropositive ( asymptomatic ) seronegative subject . 3 . No history detectable inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>BENEFIX</keyword>
	<keyword>Hemophilia B</keyword>
</DOC>